Drug Trial Radar · NCT05117632
ALTO-100 in MDD and/or PTSD
Last checked: Nov 20, 2026Latest source record: Dec 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
245
Actual
Start
Dec 20, 2021
Primary completion
Dec 1, 2022
Study completion Dec 9, 2022
Sponsor
- Lead sponsor
- Alto NeuroscienceIndustry
- Sponsor type
- Industry
- First posted
- Nov 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to collect biologically based data for defining predictors and correlates of the effects of ALTO-100.
Conditions
- Major Depressive Disorder
- Post Traumatic Stress Disorder
Interventions
ALTO-100 PO tabletDrug
one tablet twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- To understand the relationship between baseline biology and clinical outcome with ALTO-100 using the Montgomery-Åsberg Depression Rating Scale (MADRS)Time frame: Measured 5 times over 8 weeks
- To understand the relationship between baseline biology and clinical outcome with ALTO-100 using the Clinical Global Impression scale - Severity (CGI-S)Time frame: Measured 5 times over 8 weeks
- To understand the relationship between baseline biology and clinical outcome with ALTO-100 using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)Time frame: Measured 3 times over 8 weeks
- Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability of ALTO-100Time frame: From the signing of the ICF until the follow-up visit (up to 12 weeks)
- Number of Participants With Clinically Significant Vital Signs Abnormalities as a Measure of Safety and Tolerability of ALTO-100Time frame: From the signing of the ICF until the end-of-treatment visit (up to 11 weeks)
- Number of Participants With Clinically Significant Laboratory Abnormalities as a Measure of Safety and Tolerability of ALTO-100Time frame: From the signing of the ICF until the end-of-treatment visit (up to 11 weeks)
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Site 136
Tempe, Arizona
Site 139
Little Rock, Arkansas
Site 141
Costa Mesa, California
Site 118
Fresno, California
Site 116
Martinez, California
Site 116
Mather, California
Site 150
Boca Raton, Florida
Site 112
Doral, Florida
Site 155
Elgin, Illinois
Site 137
Noblesville, Indiana
Site 151
Baltimore, Maryland
Site 109
Belmont, Massachusetts
Site 108
Jackson, Mississippi
Site 142
Lincoln, Nebraska
Site 144
Las Vegas, Nevada
Site 146
Middleburg Heights, Ohio
Site 147
Fort Worth, Texas
Site 148
Fort Worth, Texas
Site 120
Houston, Texas
Site 113
Houston, Texas
Site 121
Draper, Utah
Site 105
Seattle, Washington
NTC Seattle (105a)
Tacoma, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.